GBM Day

We Research and Treat GBM: Dr. Mark Gilbert and Dr. Terri Armstrong

GBM is a monster of a disease. It takes so much from those that are affected — patients, families, caregivers, and loved ones. In the face of a glioblastoma diagnosis, families rely on love, hope, and the promise that research is advancing toward a cure. Every patient and family is different, each with their own journey, but all deserve recognition and action to defeat GBM. On the first annual Glioblastoma Awareness Day in the United States, we ask you to take one day to honor these patients, those we’ve lost, and their families.

Dr. Mark Gilbert and Dr. Terri Armstrong

“There is a lot of need for knowledge and education…Everybody is needed in this equation. All stakeholders have come together. It’s only through research that we can advance the care and treatment of patients,” Dr. Terri Armstrong says.

Terri Armstrong, PhD, is a Senior Investigator and Deputy Branch Chief, of the Neuro-Oncology Branch (NOB) of both the National Cancer Institute (NCI) and the National Institute of Neurological Disorders and Stroke (NINDS), all within the National Institutes of Health (NIH). Together with Senior Investigator and NOB Branch Chief, Mark Gilbert, MD, Dr. Armstrong conducts both clinical and laboratory research to improve the treatment and outcomes for patients with brain tumors in the NCI’s Brain Tumor Clinic.

“I don’t want to see really creative research not being able to be funded because the allocation of funding doesn’t recognize the importance of glioblastoma,” says Dr. Gilbert. “If you look at it statistically, brain tumors are 2% of [all] cancers…but their impact, both locally and globally, is much greater than that. It’s an unmet need. It is a disease where we need to make significant advances. And we can only do that if we have a critical mass of investigators and patient support and financial support.”

And despite the difficult challenge these tumors present, Drs. Gilbert and Armstrong remain positive in their outlook for glioblastoma patients. “If we can get everybody collaborating together…I think we can make significant advances in the next five years,” Dr. Gilbert adds. “The conversation that we would have at the awareness day in five years, I think, would be a very different dialogue.”

Hear more about what these two national leaders in glioblastoma research and patient care have to say about the state of the field in a video interview with NBTS CEO, David Arons.